PHST001 in adult patients with advanced relapsed and/or refractory solid tumors - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called PHTS001 (the study drug) is a safe and effective option for people who have advanced relapsed or refractory solid tumors.

¿Cuál es la Condición que se está estudiando?

Advanced Relapsed and/or Refractory Solid Tumors

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with a histologically or cytologically confirmed advanced solid tumor which has

relapsed from or been refractory to all locally available standard therapies
Do not have any form of autoimmune disease that's required treatment in the past 2 years
Are not diagnosed with HIV

For more information, contact the study team at hollie.watson@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

There is no placebo used in this study, so everyone who takes part will get the study drug.

Si decide participar en el estudio, podrá:

Get a dosing schedule to take the study drug
Get a dose of the study drug once every 3 weeks by intravenous (IV) infusion

You will get up to 34 doses of the study drug during your time in the study.

We are testing 7 different dose levels of the study drug. The dose you are assigned will depend on when you join the study.

Detalles del Estudio

Título Completo

An open-label, Phase 1a/1b, dose escalation and dose expansion study investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of PHST001 in adult patients with advanced relapsed and/or refractory solid tumors

Investigador Principal